Sector News

Trump's latest pharma-fighting plan? Use Twitter to force prices down, manufacturing to U.S.

January 16, 2017
Life sciences

President-elect Donald Trump told the Washington Post that he’ll give Medicare and Medicaid the power to negotiate drug prices, and that he’ll shame pharma into moving manufacturing to the U.S.

Pharma is fast becoming President-elect Donald Trump’s favorite whipping boy. Last month, Trump vowed to bring down drug prices. Last week, he slammed the industry for “getting away with murder.” And Saturday, he promised the Washington Post he’d subjugate drugmakers with the power of the tweet.

“They’re politically protected, but not anymore,” Trump told the newspaper.

Whereas Trump last week declared he’d institute competitive bidding to control the prices government programs pay for drugs, he reverted over the weekend to Medicare price negotiation, a mainstream proposal he’d backed during his campaign.

This time, the president-elect told the Post that he’d push for price negotiation in both Medicare and Medicaid, though the latter program is already entitled to pharma’s lowest prices.

Medicare is quite different. In fact, the legislation that created Medicare Part D, the popular prescription drug coverage for seniors, explicitly prohibited price negotiation. Proposals to change that rule have failed in Congress ever since.

Trump has claimed that Medicare could save $300 billion a year by negotiating drug prices. “We don’t do it,” he said during last year’s campaign. “Why? Because of the drug companies.”

But though targeting price negotiation may be a well worn idea in Washington, Trump promises to push the idea his own way—“just like on the airplane,” he told the Post, referring to his tweets criticizing the cost of a Lockheed Martin fighter jet. The aircraft makers’ shares tanked on Trump’s social-media attack.

Trump said he didn’t care whether his public arm-twisting sent stocks reeling, as biopharma shares did last week after his vitriolic press conference.

The incoming president also echoed previous comments about overseas drug manufacturing—a common Trump theme, but one that’s previously been focused on car companies such as Ford Motor Co. and other equipment makers, notably the air conditioning and refrigeration company Carrier.

The U.S. “needs to get our drug industry back,” Trump said during last Wednesday’s press conference. “They don’t make them here for a large extent.” To the Post, he said drugmakers “should produce” more of their meds in the U.S.

Pharma companies manufacture many products in the U.S., but also maintain enormous production capacity overseas—some designed to serve local and regional markets, the rest to supply countries around the globe. Many generic drugs are produced in India, where cheap labor helps hold costs—and prices—down.

Trump’s latest pharma comments were part of a Post interview in which the president-elect said he was down to the “final strokes” on his plan to replace the Affordable Care Act. His plan will provide “insurance for everybody” at a much lower cost and with lower deductibles than Obamacare, the president-elect claimed.

“It’ll be another plan,” Trump said in the interview. “But they’ll be beautifully covered.”

By Tracy Staton

Source: Fierce Biotech

comments closed

Related News

July 14, 2024

Flagship raises $3.6B for biotech investing

Life sciences

Flagship Pioneering said Wednesday that it’s added another $3.6 billion to its capital base, bringing the total raised since 2021 to $6.4 billion. Meanwhile, Flagship announced more than a dozen promotions and new hires in its leadership ranks. The changes include the promotions of Lovisa Afzelius and Paul Biondi to general partner and the addition of Dina Ciarimboli as general counsel and executive partner.

July 14, 2024

Mikael Dolsten set to leave Pfizer, sparking search for CSO successor

Life sciences

After 15 years at Pfizer, including a career-defining pandemic period, the chief scientific officer will leave the Big Pharma once the drugmaker finds his successor. Dolsten joined Pfizer when the company closed a megamerger with Wyeth in 2009. Pfizer made Dolsten president of worldwide R&D the following year. The executive has stayed at the top of Pfizer’s R&D tree ever since.

July 14, 2024

CDMO Lotte breaks ground on $3.3B production plant in Korea, touts growth goals

Life sciences

Late last week, Lotte Biologics broke ground on its flagship facility at the Songdo Bio Campus in Incheon International City, South Korea. The company is pitching the production effort as a key part of its quest to become one of the top 10 contract development and manufacturing organizations (CDMOs) in the world, Lotte said in a press release.

How can we help you?

We're easy to reach